Effect of Future Costs on Cost-Effectiveness of Medical Interventions Among Young Adults
Authors:
- David MeltzerDMDavid Meltzer
- Brian EglestonBEBrian Egleston
- David StoffelDSDavid Stoffel
- Erik DasbachEDErik Dasbach
- 1 June 2000
- journal article
- research article
- Published by Wolters Kluwer Health in Medical Care
- Vol. 38 (6) , 679-685
Abstract
Recent research based on a lifetime utility maximization model has suggested that cost-effectiveness analyses should account for all future costs, including medical costs for related and unrelated illnesses and nonmedical costs. This work has also shown that analyses that omit future costs are biased to favor interventions among the elderly that extend life over interventions that improve quality of life. However, the effect of including future costs on the cost-effectiveness of interventions among the young has not been studied. This article examines the effect of including future costs on the cost-effectiveness of intensive therapy for type 1 diabetes mellitus among young adults. By modifying a cost-effectiveness model based on the Diabetes Control and Complications Trial to include future costs, the effect of including future costs on the cost-effectiveness of intensive therapy for type 1 diabetes mellitus among young adults was examined. Future costs added to the model included future costs for medical expenditures for illnesses unrelated to diabetes and future nonmedical expenditures net of earnings. Intensive therapy among young adults led to approximately equal increases in the expected number of years lived before age 65, when people generally produce more than they consume, and after age 65, when the opposite tends to hold. Because the discounted value of savings due to lower mortality before age 65 exceeded the discounted value of later increases in costs due to lower mortality after age 65, accounting for future costs decreased the cost-effectiveness ratio from $22,576 to $9,626 per quality-adjusted life-year. The inclusion of future costs can significantly improve the cost-effectiveness of interventions that decrease mortality among young adults. The common practice of excluding future costs may bias cost-effectiveness analyses against such interventions.Keywords
This publication has 11 references indexed in Scilit:
- Cost effectiveness of highly active antiretroviral therapy in HIV-infected patientsAIDS, 1999
- Incorporating Future Costs in Medical Cost-Effectiveness AnalysisMedical Decision Making, 1997
- Accounting for future costs in medical cost-effectiveness analysisJournal of Health Economics, 1997
- Economic foundations of cost-effectiveness analysisJournal of Health Economics, 1997
- Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research GroupJAMA, 1996
- Differences between employed and nonemployed dialysis patientsAmerican Journal of Kidney Diseases, 1996
- Magnetic resonance angiography in progressive renal failure: A technology assessmentAmerican Journal of Kidney Diseases, 1995
- Foot infections in diabetic patients. Decision and cost-effectiveness analyses1995
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1993
- Is screening for breast cancer cost-effective?Cancer, 1992